Αρχειοθήκη ιστολογίου

Αναζήτηση αυτού του ιστολογίου

Κυριακή 13 Μαΐου 2018

SET8 is involved in the regulation of hyperglycemic memory in human umbilical endothelial cells

Abstract
Hyperglycemic memory occurs in diabetic cardiovascular complications, but the underlying mechanism remains to be elucidated. Although the depletion of SET8 leads to increased mitochondrial oxidative stress via increasing cellular reactive oxygen species (ROS) production, the role of SET8 in hyperglycemic memory-induced mitochondrial dysfunction is not well understood. Here, we investigated the role of SET8 in this setting. Our results showed that high glucose-induced vascular inflammation, ROS production and apoptosis remained at high levels even when glucose returned to normal level. Elevated glucose reduced SET8 expression, which also remained at low level after returning to normoglycemia. SET8 overexpression protected cells from elevated glucose and hyperglycemic memory-induced endothelial injury by blocking ROS accumulation, attenuating vascular inflammation, and restoring nitric oxide production. Thus, our results suggest that SET8 may be a key mediator in hyperglycemic memory.

https://ift.tt/2IiENMH

AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status

AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status

AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status, Published online: 14 May 2018; doi:10.1038/s41416-018-0086-x

AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status

https://ift.tt/2wDeO0X

Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer

Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer

Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer, Published online: 14 May 2018; doi:10.1038/s41416-018-0083-0

Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer

https://ift.tt/2Kg8OgL

Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy

Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy

Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy, Published online: 14 May 2018; doi:10.1038/s41416-018-0088-8

Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy

https://ift.tt/2IF7Ayv

Health-related quality of life after treatment for bladder cancer in England

Health-related quality of life after treatment for bladder cancer in England

Health-related quality of life after treatment for bladder cancer in England, Published online: 14 May 2018; doi:10.1038/s41416-018-0084-z

Health-related quality of life after treatment for bladder cancer in England

https://ift.tt/2wBGqUe

Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study

Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study

Heterogeneous <i>MYCN</i> amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study, Published online: 14 May 2018; doi:10.1038/s41416-018-0098-6

Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study

https://ift.tt/2wCbe7w

Endothelial Akt1 loss promotes prostate cancer metastasis via β-catenin-regulated tight-junction protein turnover

Endothelial Akt1 loss promotes prostate cancer metastasis via β-catenin-regulated tight-junction protein turnover

Endothelial Akt1 loss promotes prostate cancer metastasis via β-catenin-regulated tight-junction protein turnover, Published online: 14 May 2018; doi:10.1038/s41416-018-0110-1

Endothelial Akt1 loss promotes prostate cancer metastasis via β-catenin-regulated tight-junction protein turnover

https://ift.tt/2IB9TCJ